Published in Hepatitis Weekly, February 4th, 2002
Results of the Phase Ia study, which included 15 chronic HCV patients, indicated that HCV viral RNA levels were reduced in over half the patients following a single dose. No serious adverse events were reported.
The single-center study, under the regulation of the United States Food and Drug Administration (FDA) and Ministry of Health, Israel, was designed to test safety, tolerability and efficacy of a single-dose of XTL-002 in chronic HCV patients. The 15 patients...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly